Balanced news tone
News Sentiment
MDWD sentiment intelligence
Mediwound Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-5.7% over one week, +0.5% over four weeks, trend inactive, and near fair-value range.
Why is Cathie Wood’s ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Director at MediWound (MDWD) buys 6,000 ordinary shares in market
MediWound Ltd. director Nachum Shamir reported purchasing 6,000 ordinary shares in the open market on June 3, 2026, across two transactions at prices of $14.00 and $13.975 per share. Following these buys, Shamir directly holds 49,990 ordinary shares, in addition to RSUs, stock op
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 04 Jun 2026 19:39
- Source
- Stock Titan
MDWD - MediWound Ltd Stock Price and Quote
This page provides a detailed financial overview and news compilation for MediWound Ltd (MDWD). It includes current stock price, key financial metrics, analyst ratings, insider transactions, and a chronological list of recent news and press releases related to the company's produ
- Tone
- Positive 60/100
- Event
- Analyst action
- Published
- 04 Jun 2026 04:09
- Source
- Finviz
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30
Maxim Group has reiterated its Buy rating for MediWound (MDWD.US) and maintained a target price of $30. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
- Tone
- Positive 75/100
- Event
- Analyst action
- Published
- 02 Jun 2026 15:39
- Source
- Moomoo
MediWound (MDWD) director buys 3,537 ordinary shares on open market
MediWound Ltd. director David Morton Fox purchased 3,537 ordinary shares on the open market on June 1, 2026, with prices ranging from $13.995 to $14.23 per share. This transaction resulted in a net buy of 3,537 shares totaling $49,901. The filing also details his existing equity
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 02 Jun 2026 11:39
- Source
- Stock Titan
Director Rubinstein buys MediWound (MDWD) shares and holds multiple options
MediWound Ltd. director Samuel Rubinstein reported an open-market purchase of 150 Ordinary Shares on May 29, 2026, at $14.33 per share, increasing his direct holdings to 2,993 shares. Additionally, he indirectly holds 525 Ordinary Shares and possesses several stock option awards
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 10:39
- Source
- Stock Titan
MediWound (MDWD) Q1 Loss Of US$0.23 Per Share Reinforces Bearish Profitability Narratives
MediWound (MDWD) reported a Q1 2026 loss of US$0.23 per share on US$1.5 million in revenue, reinforcing concerns about its profitability. The company has shown consistent losses, with trailing twelve-month losses exceeding US$20 million, despite consensus narratives about expandi
- Tone
- Negative 27/100
- Event
- Earnings
- Published
- 01 Jun 2026 05:09
- Source
- Sahm
MediWound Ltd. (MDWD) Q1 2026 Earnings: Significant EPS Beat Highlights Cost Discipline - Growth Acceleration Report
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 30 May 2026 07:00
- Source
- dars.gov.et
Oppenheimer Adjusts MediWound Price Target to $32 From $33, Maintains Outperform Rating
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 28 May 2026 13:02
- Source
- MT Newswires
Will MediWound (NASDAQ:MDWD) Spend Its Cash Wisely?
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 28 May 2026 12:53
- Source
- Simply Wall St.
MediWound Ltd (MDWD) Q1 2026 Earnings Call Highlights: Strategic Collaborations and Revenue ...
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 May 2026 21:00
- Source
- GuruFocus.com
MediWound (MDWD) Q1 2026 Earnings Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 May 2026 18:34
- Source
- Motley Fool
MediWound Q1 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 May 2026 14:06
- Source
- MarketBeat
MediWound: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 May 2026 11:07
- Source
- Associated Press
MEDIWOUND ($MDWD) Releases Q1 2026 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 May 2026 07:00
- Source
- Quiver Quantitative
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 27 May 2026 07:00
- Source
- Market source
MediWound Ltd. (MDWD) Presents at European Wound Management Association (EWMA) 2026 - Slideshow
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 07:00
- Source
- Seeking Alpha
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
MediWound highlights consensus supporting debridement strategy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Apr 2026 07:00
- Source
- Investing.com
MediWound Highlights U.S. Expert Consensus Supporting EscharEx® Strategy for Chronic Wound Debridement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Apr 2026 07:00
- Source
- Quiver Quantitative
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
MediWound Updates NexoBrid Growth, EscharEx Phase III Timeline and BARDA Talks at Oppenheimer Conference
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Feb 2026 08:00
- Source
- Market source
We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business Growth
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jan 2026 08:00
- Source
- simplywall.st
MediWound Ltd. Reports Continued Enrollment in EscharEx® Phase III Trial and Strengthened Financial Position Following $30 Million Equity Financing | MDWD Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Nov 2025 08:00
- Source
- Quiver Quantitative
MediWound Ltd. Announces $30 Million Registered Direct Offering of Ordinary Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Sep 2025 07:00
- Source
- Quiver Quantitative
MediWound Ltd. Advances Development with EscharEx IND Submission Planned for Year-End and NexoBrid FDA Pediatric Approval
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Nov 2024 08:00
- Source
- Quiver Quantitative